BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31924585)

  • 1. PRIMA-1
    Jaskova Z; Pavlova S; Malcikova J; Brychtova Y; Trbusek M
    Leuk Res; 2020 Feb; 89():106288. PubMed ID: 31924585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
    Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
    Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53.
    Grellety T; Laroche-Clary A; Chaire V; Lagarde P; Chibon F; Neuville A; Italiano A
    BMC Cancer; 2015 Oct; 15():684. PubMed ID: 26463477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
    Guarini A; Peragine N; Messina M; Marinelli M; Ilari C; Cafforio L; Raponi S; Bonina S; Mariglia P; Mauro FR; Gaidano G; Del Giudice I; Foà R
    Br J Haematol; 2019 Feb; 184(3):392-396. PubMed ID: 30338509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
    Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
    Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
    Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
    Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
    Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
    Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
    Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
    [No Abstract]   [Full Text] [Related]  

  • 12. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
    Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
    Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
    Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
    Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
    J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
    Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
    Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
    Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
    Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
    Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
    Rossi D; Khiabanian H; Spina V; Ciardullo C; Bruscaggin A; Famà R; Rasi S; Monti S; Deambrogi C; De Paoli L; Wang J; Gattei V; Guarini A; Foà R; Rabadan R; Gaidano G
    Blood; 2014 Apr; 123(14):2139-47. PubMed ID: 24501221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
    Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
    Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease.
    Marinelli M; Peragine N; Di Maio V; Chiaretti S; De Propris MS; Raponi S; Tavolaro S; Mauro FR; Del Giudice I; Guarini A; Foà R
    Haematologica; 2013 Mar; 98(3):371-5. PubMed ID: 22983585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.